Premium
Bivalirudin versus heparin for peripheral vascular intervention: You get what you pay for…
Author(s) -
Kimmelstiel Carey,
Deliargyris Efthymios N.
Publication year - 2017
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.26938
Subject(s) - bivalirudin , medicine , heparin , peripheral , randomized controlled trial , cardiology , intensive care medicine , percutaneous coronary intervention , myocardial infarction
Key Points There are no randomized trials comparing bivalirudin with heparin in patients undergoing peripheral vascular intervention. Retrospective analyses suggest that bivalirudin treatment during peripheral vascular intervention is associated with less bleeding and a reduction in major adverse clinical events. Despite a higher acquisition cost compared with heparin, bivalirudin may actually provide more value and possibly reduce the total cost of care associated with peripheral interventions.